How does CTIX fast track Kevetrin? Fast track is usually

New Post Public Reply Private Reply Replies (4) Message Board
seel

How does CTIX fast track Kevetrin?

Fast track is usually applied for in phase two. It allows much greater access to FDA throughout whole trial process and will shorten review process after final trial completion. Drug must fulfill unmet medical need(can do this just by being superior to any existing therapy) and treat serious disease. After being granted fast track status, company can also apply for accelerated approval. FDA will offer much guidance on this to the company as part of the increased FDA access company has for fast track. Accelerated approval can be obtained if company can back up their case with verifiable lab data as secondary endpoint, ie, 'our drug shrinks tumors'and this approval can save them years in getting drug to market. FDA requires post marketing studies (phase 4 study) for any accelerated approval drug, ie, 'your drug shrinks tumors and that's great, but you still have to prove that it helps people live longer'.

http://www.nationalaglawcenter.org/assets/crs/RS22814.pdf

What we do know from material on the FDA website:
! Manufacturers have requested Fast Track designation for 569 drugs and
195 biological products since the Fast Track program was set into law.
! FDA granted the designation to 74.5% of those drug requests and 63.6%
of those biologics requests.
! Of products with Fast Track designation, FDA eventually approved
10.6% of the drugs and licensed 17.7% of the biologics.6

Fast Track submissions in theory differ from routine NDA/BLA submissions because
they address unmet needs in the treatment of life-threatening or serious conditions.
Similar criteria apply to drugs that FDA gives Priority Review status. In fact, 80% of Fast
Track NDA approvals were also given Priority Review, as were all of the approved Fast
Track BLAs. Again, FDA makes public detailed data only regarding the products that it
approves/license.

http://www.fas.org/sgp/crs/misc/R41983.pdf

Accelerated approval. FDA regulations allow “accelerated approval” of a drug or biologic product that provides a“meaningful therapeutic benefit ... over existing treatments.” The rule covers two situations. The first allows approval to be based on clinical trials that, rather than using standard outcome measures such as survival or disease progression, use “a surrogate endpoint that is reasonably likely ... to predict clinical benefit.” The second situation addresses drugs whose use FDA considers safe and effective only under set restrictions that could include limited
prescribing or dispensing. FDA usually requires postmarketing studies of products approved this way.
Fast track. The Food and Drug Administration Modernization Act of 1997 (FDAMA, P.L. 105-115) directed the Secretary to create a mechanism whereby FDA could designate as “Fast Track” certain products that meet two criteria. First, the product must concern a serious or life-threatening condition; second, it must have the potential to address an unmet medical need. Once FDA grants a Fast Track designation, it encourages the manufacturer to meet with the agency to discuss development plans and strategies before the formal submission of an NDA. Such early
interaction can help clarify elements of clinical study design and presentation that if absent at NDA submission could delay approval decisions. However, FDA makes similar interactions available to any sponsor who seeks FDA consultation throughout the stages of drug development.
Priority review.

Unlike Fast Track or Accelerated Approval, the Priority Review process begins only when a manufacturer officially submits an NDA. Priority Review, therefore, does not alter the timing or content of steps taken in a drug’s development or testing for safety and effectiveness. Although Priority Review is not explicitly required by law, FDA has established it in practice, and various statutes, such as the Prescription Drug User Fee Act (PDUFA), refer to and sometimes require it. When FDA determines that a product would address an unmet need, it places it through Priority Review. That designation results in an average turnaround time (from completed application to approval decision) of approximately 6 months, rather than the 10-month average for Standard Review.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 16

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 36

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 43

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 12

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 78

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus

Updated Category News Views 22

A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...

Continue Reading
Worker Pullback Is a Cost Problem Employers Ignore

Updated Category News Views 31

Somewhere between a job description and an unpaid favor, a lot of corporate productivity appears to be quietly leaking out. MyPerfectResume’s July 2026 survey of 1,000 U.S. workers says 78% have intentionally done only the minimum needed to keep their jobs at least once. That is not a cute workplace-culture headline. It is a warning flare about discretionary...

Continue Reading
We Are All Human Gala Puts Latino Leadership Center Stage

Updated Category News Views 54

Recognition can sound like soft stuff until a room full of decision-makers decides whose work deserves the microphone. That was the real point of We Are All Human’s sixth annual Gala at Cipriani Wall Street in New York on Nov. 20, 2026: put Latino leadership, cultural influence and economic contribution in plain view rather than treating them as a decorative footnote....

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 0

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of the Nanobiotechnology Market Growth

Updated Category News Views 134

Understanding the Nanobiotechnology Market Trends The nanobiotechnology market has emerged as a rapidly expanding sector, projected to surge from USD 189 billion in 2025 to USD 420.2 billion by 2034, achieving a remarkable CAGR of 9.37% over the forecast period. This growth reflects the increasing integration of nanotechnology in a variety of applications, particularly...

Continue Reading
Transforming a Decade of Investment: The Ensign Group Journey

Updated Category News Views 323

Transforming a Decade of Investment: The Ensign Group Journey Ensign Group (NASDAQ: ENSG) has shown a remarkable performance over the last decade, surpassing the market with an impressive annualized growth rate of 12.64%. This extraordinary growth results in an average annual return of 23.92%, highlighting the potential benefits of long-term investments. Significance of a...

Continue Reading
Chaco Collaborates with Marley Family for Unique Sandals

Updated Category News Views 121

Chaco and Marley Family Unite for a Meaningful Collection Chaco, a premier sandal brand known for its commitment to quality and comfort, has teamed up with the Marley family to create a limited-edition collection inspired by the iconic Bob Marley. This exciting collaboration seeks to embody Marley's legendary message of love, unity, and connection, encouraging wearers to...

Continue Reading
Trump Mobile Launches Game-Changing Wireless Service for All

Updated Category News Views 189

Trump Mobile Launches a Revolutionary Wireless Service In an exciting announcement that aims to reshape the telecommunications landscape, Trump Mobile has introduced its new cellular service called T1 Mobile. This innovative service promises exceptional connectivity and unparalleled value tailored specifically for hardworking Americans. Introducing the 47 Plan for...

Continue Reading
Travel Smart: Unlock the Secrets to Affordable Flights

Updated Category News Views 168

Expedia’s 2025 Air Hacks Report: Unlocking Air Travel Secrets Expedia’s latest report, focusing on air travel hacks, sheds light on the surprising truth about flight pricing. Contrary to popular belief, the peak travel month of July is actually the most affordable time to fly for those leaving from Canadian airports. In fact, travelers can anticipate airfares in July...

Continue Reading